What are analysts'target prices for Inovio Pharmaceuticals stock?
6 brokerages have issued 12-month target prices for Inovio Pharmaceuticals' shares. Their forecasts range from $6.00 to $35.00. On average, they anticipate Inovio Pharmaceuticals' stock price to reach $12.60 in the next year.
Who is the CEO of Inovio Pharmaceuticals?
12 employees have rated Inovio Pharmaceuticals CEO J. Joseph Kim on Glassdoor.com. J. Joseph Kim has an approval rating of 82% among Inovio Pharmaceuticals' employees. Who are some of Inovio Pharmaceuticals' key competitors?
How much money does Inovio make a year?
Inovio Pharmaceuticals has a market capitalization of $698.48 million and generates $7.41 million in revenue each year. The biopharmaceutical company earns $-166.41 million in net income (profit) each year or ($1.09) on an earnings per share basis. How many employees does Inovio Pharmaceuticals have?
Will Inovio share my data with any third party?
At INOVIO, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below.
Is Inovio stock a buy or sell?
According to the issued ratings of 5 analysts in the last year, the consensus rating for Inovio Pharmaceuticals stock is Hold based on the current 5 hold ratings for INO. The average twelve-month price prediction for Inovio Pharmaceuticals is $5.75 with a high price target of $10.00 and a low price target of $3.00.
What is the target price Inovio stock?
Stock Price Forecast The 4 analysts offering 12-month price forecasts for Inovio Pharmaceuticals Inc have a median target of 2.50, with a high estimate of 8.00 and a low estimate of 1.00. The median estimate represents a +47.93% increase from the last price of 1.69.
Is inovio undervalued?
The current market capitalization of $850 million includes some assumption of success, but since I expect VGX-3100 revenue to top $250 million annually at some point, in my view Inovio is currently undervalued....About INO.SymbolLast Price% ChgINO2.2210.45%Jan 26, 2022
Does inovio pay a dividend?
INO does not currently pay a dividend.
Why is INO stock going up?
Technical Analysis Of INO Stock Inovio stock hit a high mark of 33.79 in June 2020 after the biotech company received a $71 million contract from the U.S. Department of Defense to scale up manufacturing for its coronavirus vaccine.
Who owns Inovio stock?
Top 10 Owners of Inovio Pharmaceuticals IncStockholderStakeShares ownedBlackRock Fund Advisors6.74%15,433,492The Vanguard Group, Inc.4.77%10,917,466D. E. Shaw & Co. LP2.40%5,499,823Geode Capital Management LLC1.48%3,393,0336 more rows
Why is inovio stock dropping?
[Updated: Dec 17, 2021] INO Stock Decline This can be attributed to the spread of the new Covid-19 variant - Omicron. Inovio is developing INO-4800 - its Covid-19 vaccine candidate, which is now in late stage clinical trials and it is still several months before it can hit the market, subject to regulatory approval.
Should I buy or sell Inovio Pharmaceuticals stock right now?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last twelve months. There are currently 5 ho...
What is Inovio Pharmaceuticals' stock price forecast for 2022?
5 Wall Street research analysts have issued 12-month price objectives for Inovio Pharmaceuticals' shares. Their forecasts range from $3.00 to $35.0...
How has Inovio Pharmaceuticals' stock price performed in 2022?
Inovio Pharmaceuticals' stock was trading at $4.99 on January 1st, 2022. Since then, INO shares have decreased by 69.7% and is now trading at $1.51...
Are investors shorting Inovio Pharmaceuticals?
Inovio Pharmaceuticals saw a drop in short interest in the month of May. As of May 31st, there was short interest totaling 34,410,000 shares, a dro...
When is Inovio Pharmaceuticals' next earnings date?
Inovio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for...
How were Inovio Pharmaceuticals' earnings last quarter?
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) posted its earnings results on Tuesday, May, 10th. The biopharmaceutical company reported ($0.36) earning...
When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?
Inovio Pharmaceuticals shares reverse split on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of s...
Who are Inovio Pharmaceuticals' key executives?
Inovio Pharmaceuticals' management team includes the following people: Dr. J. Joseph Kim Ph.D. , CEO, Pres & Director (Age 53, Pay $1.31M) Mr. P...
What is J. Joseph Kim's approval rating as Inovio Pharmaceuticals' CEO?
12 employees have rated Inovio Pharmaceuticals CEO J. Joseph Kim on Glassdoor.com . J. Joseph Kim has an approval rating of 82% among Inovio Pharm...
When did Inovio Pharmaceuticals reverse split?
When did the 1-4 reverse split happen?
Inovio Pharmaceuticals shares reverse split on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares ...
Nasdaq Global Select
The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.
Environmental, Social, and Governance Rating
A biomedical company which deals in developing human applications of electroporation, which uses brief, controlled electrical pulses to increase cellular uptake of a useful biopharmaceuticals.
Business Summary
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
Cepton CEO says it avoided lidar SPAC pack's swoon thanks to GM contract
A biomedical company which deals in developing human applications of electroporation, which uses brief, controlled electrical pulses to increase cellular uptake of a useful biopharmaceuticals.
Lidar maker Quanergy's SPAC merger provides less capital than expected
The San Jose company is now the only one of eight lidar companies from the Bay Area whose stock is trading above the price it went public at.
